<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619159</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-22-10-04</org_study_id>
    <nct_id>NCT05619159</nct_id>
  </id_info>
  <brief_title>the Value of Immunohistochemical Expression of Moesin in Endometrial Hyperplasia and Endometrial Carcinoma</brief_title>
  <official_title>the Value of Immunohistochemical Expression of Moesin in Endometrial Hyperplasia and Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometrial carcinoma (EC) is the most prevalent invasive carcinoma of the female genital&#xD;
      tract in developed countries, while it ranks as the second most frequently occurring neoplasm&#xD;
      of women in developing countries, after carcinoma of the cervix uteri. The vast majority of&#xD;
      ECs occur in perimenopausal and postmenopausal women .&#xD;
&#xD;
      ECs are classified into two distinct phenotypes; type I which represents more than 80% of all&#xD;
      cases of ECs, it has a favorable prognosis. This type is linked to excess, unopposed&#xD;
      hyper-estrogenic condition and it is almost always preceded by endometrial hyperplasia. On&#xD;
      the contrary, type II endometrial carcinoma is less common than type I, representing less&#xD;
      than 10% of all cases of ECs. Type II endometrial carcinomas are high grade, poorly&#xD;
      differentiated and estrogen-independent tumors .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2022</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The value of immunohistochemical expression of moesin in endometrial hyperplasia and endometrial carcinoma</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate immunohistochemical expression of moesin in normal, hyperplasic and neoplastic endometrial tissues , correlate this expression with different clinicopathologic parameters of endometrial carcinoma and to evaluate the role of moesin as prognostic marker in progression from preinvasive lesions of the endometrium to endometrial carcinoma.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endometrial Cancer and Endometrial Hyperplasia</condition>
  <arm_group>
    <arm_group_label>endometrial carcinoma smples</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>endometrial hyperplasia samples</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>microscopic pathological evaluation</intervention_name>
    <description>description of moesin expression between endometrial hyperplasia and endometrial carcinoma</description>
    <arm_group_label>endometrial carcinoma smples</arm_group_label>
    <arm_group_label>endometrial hyperplasia samples</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        females presented to gynecology department in sohag university hospital and sohag oncology&#xD;
        center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hysterectomy specimens diagnosed as endometrial hyperplasia and endometrial&#xD;
             adenocarcinoma.&#xD;
&#xD;
          -  All cases of endometrial biopsies obtained by curettage (D&amp;C) diagnosed as endometrial&#xD;
             hyperplasia.&#xD;
&#xD;
          -  Cases of cyclical endometrium obtained from endometrial curettage or hysterectomy&#xD;
             specimens done for pathological conditions other than hyperplastic or neoplastic&#xD;
             endometrial lesions.&#xD;
&#xD;
          -  Complete clinical data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of preoperative chemotherapy and /or radiotherapy.&#xD;
&#xD;
          -  Biopsies with predominantly blood clots.&#xD;
&#xD;
          -  Insufficient or tiny tissue biopsies.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>nermine a abd el fattah, resident doctor</last_name>
    <phone>01018254748</phone>
    <email>nermine_abbas_post@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>afaf t el nashar, professor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sohag University Hospital</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Magdy M Amin, professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Frose J, Chen MB, Hebron KE, Reinhardt F, Hajal C, Zijlstra A, Kamm RD, Weinberg RA. Epithelial-Mesenchymal Transition Induces Podocalyxin to Promote Extravasation via Ezrin Signaling. Cell Rep. 2018 Jul 24;24(4):962-972. doi: 10.1016/j.celrep.2018.06.092.</citation>
    <PMID>30044991</PMID>
  </reference>
  <reference>
    <citation>Wang H, Xiao X, Li Z, Luo S, Hu L, Yi H, Xiang R, Zhu Y, Wang Y, Zhu L, Xiao L, Dai C, Aziz A, Yuan L, Cui Y, Li R, Gong F, Liu X, Liang L, Peng H, Zhou H, Liu J. Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma. Cancer Lett. 2022 Jul 1;537:215647. doi: 10.1016/j.canlet.2022.215647. Epub 2022 Mar 17.</citation>
    <PMID>35306105</PMID>
  </reference>
  <reference>
    <citation>Mandelbaum RS, Ciccone MA, Nusbaum DJ, Khoshchehreh M, Purswani H, Morocco EB, Smith MB, Matsuzaki S, Dancz CE, Ozel B, Roman LD, Paulson RJ, Matsuo K. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. Am J Obstet Gynecol. 2020 Jul;223(1):103.e1-103.e13. doi: 10.1016/j.ajog.2019.12.273. Epub 2020 Jan 21.</citation>
    <PMID>31978437</PMID>
  </reference>
  <reference>
    <citation>Yuan O, Ugale A, de Marchi T, Anthonydhason V, Konturek-Ciesla A, Wan H, Eldeeb M, Drabe C, Jassinskaja M, Hansson J, Hidalgo I, Velasco-Hernandez T, Cammenga J, Magee JA, Nimeus E, Bryder D. A somatic mutation in moesin drives progression into acute myeloid leukemia. Sci Adv. 2022 Apr 22;8(16):eabm9987. doi: 10.1126/sciadv.abm9987. Epub 2022 Apr 20.</citation>
    <PMID>35442741</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 23, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Nermin Abbas</investigator_full_name>
    <investigator_title>resident doctor pathology in sohag oncology center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Endometrial Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

